AlHilli, Mariam M <br/><br/>
In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma.  [electronic resource] 

 -  Gynecologic oncology  Nov 2016 
 - 379-388 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1095-6859 
<br/><br/><label>Standard No.: </label>10.1016/j.ygyno.2016.08.328  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>DNA-Binding Proteins--analysis<br/>Female<br/>Genes, BRCA2<br/>Homologous Recombination<br/>Humans<br/>Indazoles--therapeutic use<br/>Ovarian Neoplasms--drug therapy<br/>Piperidines--therapeutic use<br/>Poly(ADP-ribose) Polymerase Inhibitors--therapeutic use<br/>Promoter Regions, Genetic